AMPIO PHARMACEUTICALS, INC. (NYSEMKT:AMPE) Files An 8-K Entry into a Material Definitive Agreement

AMPIO PHARMACEUTICALS, INC. (NYSEMKT:AMPE) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

Item1.01 Entry into a Material Definitive Agreement.

The information set forth under Item 5.02 of this Current Report
on Form 8-K is hereby incorporated in this Item 1.01 by

Item5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.

Amendment of Employment Agreement with Michael Macaluso

On March9, 2017, Ampio Pharmaceuticals, Inc. (the Company)
entered into an amendment to the Employment Agreement, effective
January9, 2012, with Michael Macaluso, the Chief Executive
Officer of the Company (the Amendment, and the Employment
Agreement as amended, the Employment Agreement). Under the
Amendment, the term of Mr.Macalusos Employment Agreement was
extended through January9, 2020. In addition, in connection with
the Amendment, Mr.Macaluso was granted an option to purchase
400,000 shares of the Companys common stock. The option is
exercisable for a period of ten years at an exercise price per
share equal to $0.81, the quoted closing price of the Companys
common stock on March9, 2017. The option vests as follows:
133,333 shares vest on each of January9, 2018 and January9, 2019
and 133,334 shares vest on January9, 2020, subject to vesting
acceleration provisions in accordance with the Employment

The description of the Amendment set forth herein does not
purport to be complete and is qualified in its entirety by
reference to the full text thereof, which is attached hereto as
Exhibit 10.1.

Item9.01 Financial Statements and Exhibits.

Exhibit Number


10.1 Amendment to Employment Agreement between Ampio
Pharmaceuticals, Inc. and Michael Macaluso, dated March9,


Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.


AMPIO PHARMACEUTICALS, INC. (NYSEMKT:AMPE) closed its last trading session up +0.008 at 0.807 with 156,970 shares trading hands.

An ad to help with our costs